Quality of life and willingness to pay for receiving hemodialysis in patients who received peritoneal dialysis in Thailand

Q4 Pharmacology, Toxicology and Pharmaceutics Pharmaceutical Sciences Asia Pub Date : 2022-01-01 DOI:10.29090/psa.2022.04.22.054

Wanchana Singhan, U. Permsuwan, S. Vongsanim, Yuttitham Suteeka, S. Deeprom

{"title":"Quality of life and willingness to pay for receiving hemodialysis in patients who received peritoneal dialysis in Thailand","authors":"Wanchana Singhan, U. Permsuwan, S. Vongsanim, Yuttitham Suteeka, S. Deeprom","doi":"10.29090/psa.2022.04.22.054","DOIUrl":null,"url":null,"abstract":"This cross-sectional study was conducted to evaluate quality of life (QoL), willingness to pay (WTP) for receiving hemodialysis (HD), and factors influencing QoL in patients who received peritoneal dialysis (PD) in Thailand. Data of PD patients visiting secondary or tertiary hospitals from December 2020 through June 2021 were collected. EuroQoL EQ-5D-5L questionnaire was used to evaluate QoL. After the patients completed the questionnaire, they were interviewed using the contingent valuation method to derive their WTP for switching to HD. Patients randomly picked up one payment card as an initial price for receiving HD, then bidding by 100 Thai Baht (THB) up and down to reach the maximum affordable WTP amount. Multiple linear regression was used to identify factors affecting QoL. A total of 102 patients were included in this study. The mean age was 58 years. EQ-5D utility score was 0.71±0.32. Five variables were the factors that affect QoL included serum albumin, hospitalization, age, urine output, and hemoglobin level. Average WTP was 233±293 THB (7.2±9.0 USD) per HD session. Quality of life among these study patients was slightly higher than reported in Thai patients with low hemoglobin level. Treatment anemia to reach hemoglobin target and preservation of residual urine output might improve QoL. The average WTP for switching to HD among PD patients was only one-sixth of general billing price for HD.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Sciences Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29090/psa.2022.04.22.054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

This cross-sectional study was conducted to evaluate quality of life (QoL), willingness to pay (WTP) for receiving hemodialysis (HD), and factors influencing QoL in patients who received peritoneal dialysis (PD) in Thailand. Data of PD patients visiting secondary or tertiary hospitals from December 2020 through June 2021 were collected. EuroQoL EQ-5D-5L questionnaire was used to evaluate QoL. After the patients completed the questionnaire, they were interviewed using the contingent valuation method to derive their WTP for switching to HD. Patients randomly picked up one payment card as an initial price for receiving HD, then bidding by 100 Thai Baht (THB) up and down to reach the maximum affordable WTP amount. Multiple linear regression was used to identify factors affecting QoL. A total of 102 patients were included in this study. The mean age was 58 years. EQ-5D utility score was 0.71±0.32. Five variables were the factors that affect QoL included serum albumin, hospitalization, age, urine output, and hemoglobin level. Average WTP was 233±293 THB (7.2±9.0 USD) per HD session. Quality of life among these study patients was slightly higher than reported in Thai patients with low hemoglobin level. Treatment anemia to reach hemoglobin target and preservation of residual urine output might improve QoL. The average WTP for switching to HD among PD patients was only one-sixth of general billing price for HD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

泰国接受腹膜透析患者的生活质量和接受血液透析的支付意愿

本横断面研究旨在评估泰国接受腹膜透析(PD)患者的生活质量(QoL)、接受血液透析(HD)的支付意愿(WTP)以及影响生活质量的因素。收集2020年12月至2021年6月在二级或三级医院就诊的PD患者数据。采用EuroQoL EQ-5D-5L问卷评价生活质量。在患者完成问卷后，使用条件评估法对他们进行访谈，得出他们切换到HD的WTP。患者随机选择一张支付卡作为接受HD的初始价格，然后以100泰铢(THB)上下竞标，以达到可承受的最高WTP金额。采用多元线性回归分析确定影响生活质量的因素。本研究共纳入102例患者。平均年龄为58岁。EQ-5D效用评分为0.71±0.32。影响生活质量的因素包括血清白蛋白、住院时间、年龄、尿量和血红蛋白水平。平均WTP为233±293泰铢(7.2±9.0美元)。这些研究患者的生活质量略高于泰国血红蛋白水平低的患者。治疗贫血达到血红蛋白指标，保留残尿量可改善生活质量。PD患者切换到HD的平均WTP仅为HD一般计费价格的六分之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmaceutical Sciences Asia Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： The Pharmaceutical Sciences Asia (PSA) journal is a double-blinded peer-reviewed journal in English published quarterly, by the Faculty of Pharmacy, Mahidol University, Thailand. The PSA journal is formerly known as Mahidol University Journal of Pharmaceutical Sciences and committed to the timely publication of innovative articles and reviews. This journal is available in both printed and electronic formats. The PSA journal aims at establishing a publishing house that is open to all. It aims to disseminate knowledge; provide a learned reference in the field; and establish channels of communication between academic and research expert, policy makers and executives in industry and investment institutions. The journal publishes research articles, review articles, and scientific commentaries on all aspects of the pharmaceutical sciences and multidisciplinary field in health professions and medicine. More specifically, the journal publishes research on all areas of pharmaceutical sciences and related disciplines: Clinical Pharmacy Drug Synthesis and Discovery Targeted-Drug Delivery Pharmaceutics Biopharmaceutical Sciences Phytopharmaceutical Sciences Pharmacology and Toxicology Pharmaceutical Chemistry Nutraceuticals and Functional Foods Natural Products Social, Economic, and Administrative Pharmacy Clinical Drug Evaluation and Drug Policy Making Antimicrobials, Resistance and Infection Control Pharmacokinetics and Pharmacodynamics.